---
document_datetime: 2025-12-29 13:27:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/imvanex.html
document_name: imvanex.html
version: success
processing_time: 0.1218745
conversion_datetime: 2025-12-30 01:36:26.928208
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Imvanex

[RSS](/en/individual-human-medicine.xml/65501)

##### Authorised

This medicine is authorised for use in the European Union

smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara) Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Imvanex](#news-on)
- [More information on Imvanex](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Imvanex is a vaccine used to protect against smallpox in adults and adolescents aged 12 years and older.

Smallpox was officially declared eradicated in 1980, with the last known case of the disease occurring in 1977. This vaccine will be used when it is considered necessary to protect against smallpox in accordance with official recommendations.

Imvanex can also be used to protect adults and adolescents aged 12 years and older from mpox (formerly monkeypox) and disease caused by the vaccinia virus.

Imvanex contains an attenuated (weakened) form of the vaccinia virus called 'modified vaccinia virus Ankara', which is related to the smallpox and mpox viruses.

Expand section

Collapse section

## How is Imvanex used?

Imvanex is given by injection under the skin, preferably in the upper arm. People who have not been previously vaccinated against smallpox, mpox or vaccinia viruses should receive two doses, with the second dose given at least 28 days after the first.

If a booster dose is considered necessary in people previously vaccinated, a single dose should be given. People with a weakened immune system (the body's natural defences) who require a booster should receive two doses, with the second dose given at least 28 days after the first.

The vaccine can only be obtained with a prescription. It should be used in accordance with official recommendations issued at national level by public health bodies.

For more information about using Imvanex, see the package leaflet or contact your doctor or pharmacist.

## How does Imvanex work?

Imvanex works by preparing the body to defend itself against infection with the variola (smallpox), mpox or vaccinia viruses. It contains a weakened form of the vaccinia virus called 'modified vaccinia virus Ankara', a virus that is closely related to the smallpox and mpox viruses but does not cause disease in humans and cannot reproduce in human cells.

When a person is given Imvanex, the immune system recognises the virus in the vaccine as 'foreign' and makes antibodies against it. If, later on, the person comes into contact with similar viruses, their immune system will be able to kill the viruses and help protect against disease. Because of the similarity between the virus in Imvanex and the smallpox and mpox viruses, antibodies produced against it are expected to protect against the diseases caused by these viruses.

## What benefits of Imvanex have been shown in studies?

Imvanex was shown in studies to be effective at triggering the production of antibodies to a level expected to provide protection against smallpox.

Five main studies involved over 2,000 adults, including people with HIV and atopic dermatitis (an itchy skin condition caused by an overactive immune system) and adults who had been vaccinated against smallpox in the past. Two of the studies specifically looked at the effectiveness of Imvanex as a booster. A subsequent study in 433 people who had not been vaccinated before found that the level of protective antibodies after vaccination with Imvanex was at least as high as with a conventional smallpox vaccine. It is not yet known how long the protection will last.

Interim results from an ongoing study involving 211 adults and 315 adolescents aged 12 to 17 years found that the immune response to two doses of Imvanex in adolescents, as measured by the levels of antibodies against the vaccinia virus, was comparable to that seen in adults.

Data from several animal studies showed protection against mpox in non-human primates vaccinated with Imvanex and then exposed to the mpox virus.

Imvanex is also expected to protect against the disease caused by vaccinia virus, since the vaccine is based on a modified version of vaccinia virus.

## What are the risks associated with Imvanex?

For the full list of side effects and restrictions with Imvanex, see the package leaflet.

The most common side effects with Imvanex are usually mild or moderate and get better within seven days after vaccination. In adults, the most common side effects (which may affect more than 1 in 10 people) include headache, nausea, myalgia (muscle pain), tiredness and injection site reactions (pain, redness, swelling, hardening and itching). The side effects in children from 12 years old are similar to those seen in adults.

Imvanex must not be used in patients who are hypersensitive (allergic) to the active substance or any of the substances found at trace levels, such as chicken protein, benzonase, gentamicin and ciprofloxacin.

## Why is Imvanex authorised in the EU?

The European Medicines Agency considered that Imvanex is effective at triggering the production of antibodies against smallpox to a level that provides protection at least as high as that from conventional smallpox vaccines. The vaccinia virus in Imvanex cannot replicate in human cells and hence is less likely to cause side effects than conventional smallpox vaccines. Imvanex would therefore be beneficial for people who cannot be given vaccines containing replicating viruses, such as patients with a weakened immune system.

For the prevention of mpox, the Agency considered that the effectiveness of Imvanex could be inferred from animal studies. In addition, because of the similarity between the virus in Imvanex ('modified vaccinia virus Ankara') and smallpox, mpox and vaccinia viruses, antibodies produced against it are expected to protect against mpox, smallpox as well as disease caused by the vaccinia virus.

The safety profile of Imvanex is considered favourable, with vaccinated people experiencing mild to moderate side effects. The Agency therefore decided that Imvanex's benefits are greater than its risks and it can be authorised for use in the EU.

Imvanex has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Imvanex due to the rarity of the diseases. The company must provide further data on Imvanex. It must submit data on the vaccine's benefits and risks from an observational study in people who are given the vaccine, if an outbreak of smallpox occurs in the future. In addition, the company will collect data from an observational study carried out during the 2022 mpox outbreak in Europe to confirm the effectiveness of the vaccine in protecting against mpox. The company will also submit the final results of the ongoing study involving 12- to 17-year-old adolescents to provide further information on the safety of the vaccine in this age group.

Every year, the Agency will review any new information that becomes available.

## What measures are being taken to ensure the safe and effective use of Imvanex?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imvanex have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Imvanex are continuously monitored. Side effects reported with Imvanex are carefully evaluated and any necessary action taken to protect patients.

## Other information about Imvanex

Imvanex received a marketing authorisation valid throughout the EU on 31 July 2013.

Imvanex : EPAR - Medicine overview

English (EN) (126.18 KB - PDF)

**First published:** 16/08/2013

**Last updated:** 20/09/2024

[View](/en/documents/overview/imvanex-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-307)

български (BG) (141.3 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/bg/documents/overview/imvanex-epar-medicine-overview_bg.pdf)

español (ES) (115.5 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/es/documents/overview/imvanex-epar-medicine-overview_es.pdf)

čeština (CS) (138.64 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/cs/documents/overview/imvanex-epar-medicine-overview_cs.pdf)

dansk (DA) (115.49 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/da/documents/overview/imvanex-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.7 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/de/documents/overview/imvanex-epar-medicine-overview_de.pdf)

eesti keel (ET) (113.71 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/et/documents/overview/imvanex-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.87 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/el/documents/overview/imvanex-epar-medicine-overview_el.pdf)

français (FR) (117.06 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/fr/documents/overview/imvanex-epar-medicine-overview_fr.pdf)

hrvatski (HR) (137.96 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/hr/documents/overview/imvanex-epar-medicine-overview_hr.pdf)

italiano (IT) (114.9 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/it/documents/overview/imvanex-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (146.69 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/lv/documents/overview/imvanex-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (147.92 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/lt/documents/overview/imvanex-epar-medicine-overview_lt.pdf)

magyar (HU) (138.71 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/hu/documents/overview/imvanex-epar-medicine-overview_hu.pdf)

Malti (MT) (149.58 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/mt/documents/overview/imvanex-epar-medicine-overview_mt.pdf)

Nederlands (NL) (115.51 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/nl/documents/overview/imvanex-epar-medicine-overview_nl.pdf)

polski (PL) (142.31 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/pl/documents/overview/imvanex-epar-medicine-overview_pl.pdf)

português (PT) (116.68 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/pt/documents/overview/imvanex-epar-medicine-overview_pt.pdf)

română (RO) (137.1 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/ro/documents/overview/imvanex-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.08 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/sk/documents/overview/imvanex-epar-medicine-overview_sk.pdf)

slovenščina (SL) (135.47 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/sl/documents/overview/imvanex-epar-medicine-overview_sl.pdf)

Suomi (FI) (113.5 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/fi/documents/overview/imvanex-epar-medicine-overview_fi.pdf)

svenska (SV) (114.64 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

16/10/2024

[View](/sv/documents/overview/imvanex-epar-medicine-overview_sv.pdf)

Imvanex : EPAR - Risk management plan

English (EN) (2.07 MB - PDF)

**First published:** 16/10/2024

**Last updated:** 24/01/2025

[View](/en/documents/rmp/imvanex-epar-risk-management-plan_en.pdf)

## Product information

Imvanex : EPAR - Product information

English (EN) (514.07 KB - PDF)

**First published:** 16/08/2013

**Last updated:** 20/10/2025

[View](/en/documents/product-information/imvanex-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-777)

български (BG) (601.08 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/bg/documents/product-information/imvanex-epar-product-information_bg.pdf)

español (ES) (474.96 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/es/documents/product-information/imvanex-epar-product-information_es.pdf)

čeština (CS) (533.52 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/cs/documents/product-information/imvanex-epar-product-information_cs.pdf)

dansk (DA) (485.95 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/da/documents/product-information/imvanex-epar-product-information_da.pdf)

Deutsch (DE) (483.39 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/de/documents/product-information/imvanex-epar-product-information_de.pdf)

eesti keel (ET) (458.8 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/et/documents/product-information/imvanex-epar-product-information_et.pdf)

ελληνικά (EL) (568.92 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/el/documents/product-information/imvanex-epar-product-information_el.pdf)

français (FR) (577.68 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/fr/documents/product-information/imvanex-epar-product-information_fr.pdf)

hrvatski (HR) (530.55 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/hr/documents/product-information/imvanex-epar-product-information_hr.pdf)

íslenska (IS) (503.55 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/is/documents/product-information/imvanex-epar-product-information_is.pdf)

italiano (IT) (544.11 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/it/documents/product-information/imvanex-epar-product-information_it.pdf)

latviešu valoda (LV) (591.53 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/lv/documents/product-information/imvanex-epar-product-information_lv.pdf)

lietuvių kalba (LT) (575.4 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/lt/documents/product-information/imvanex-epar-product-information_lt.pdf)

magyar (HU) (616.07 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/hu/documents/product-information/imvanex-epar-product-information_hu.pdf)

Malti (MT) (578.47 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/mt/documents/product-information/imvanex-epar-product-information_mt.pdf)

Nederlands (NL) (473.86 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/nl/documents/product-information/imvanex-epar-product-information_nl.pdf)

norsk (NO) (508.39 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/no/documents/product-information/imvanex-epar-product-information_no.pdf)

polski (PL) (618.45 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/pl/documents/product-information/imvanex-epar-product-information_pl.pdf)

português (PT) (509.56 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/pt/documents/product-information/imvanex-epar-product-information_pt.pdf)

română (RO) (592.4 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/ro/documents/product-information/imvanex-epar-product-information_ro.pdf)

slovenčina (SK) (547.61 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/sk/documents/product-information/imvanex-epar-product-information_sk.pdf)

slovenščina (SL) (564.32 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/sl/documents/product-information/imvanex-epar-product-information_sl.pdf)

Suomi (FI) (541.43 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

20/10/2025

[View](/fi/documents/product-information/imvanex-epar-product-information_fi.pdf)

**Latest procedure affecting product information:** VR/0000291496 16/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Imvanex : EPAR - All Authorised presentations

English (EN) (27.82 KB - PDF)

**First published:** 16/08/2013

**Last updated:** 10/09/2024

[View](/en/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-801)

български (BG) (42.2 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/bg/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.01 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/es/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.57 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/cs/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.83 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/da/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.17 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/de/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.37 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/et/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.39 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/el/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_el.pdf)

français (FR) (15.34 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/fr/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.27 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/hr/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (15.15 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/is/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.99 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/it/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (41.9 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/lv/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.51 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/lt/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.56 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/hu/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (43.3 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/mt/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.17 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/nl/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (22.07 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/no/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_no.pdf)

polski (PL) (38.19 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/pl/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.12 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/pt/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_pt.pdf)

română (RO) (36.57 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/ro/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.8 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/sk/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.61 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/sl/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (18.42 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/fi/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.47 KB - PDF)

**First published:**

16/08/2013

**Last updated:**

10/09/2024

[View](/sv/documents/all-authorised-presentations/imvanex-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Imvanex Active substance modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus International non-proprietary name (INN) or common name smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara) Therapeutic area (MeSH)

- Smallpox Vaccine
- Monkeypox virus

Anatomical therapeutic chemical (ATC) code J07BX

### Pharmacotherapeutic group

Other viral vaccines

### Therapeutic indication

Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in individuals 12 years of age and older (see sections 4.4 and 5.1). The use of this vaccine should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/002596

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Bavarian Nordic A/S

Hejreskovvej 10 A

Opinion adopted 30/05/2013 Marketing authorisation issued 31/07/2013 Revision 31

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Imvanex : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (153.15 KB - PDF)

**First published:** 16/06/2025

**Last updated:** 20/10/2025

[View](/en/documents/procedural-steps-after/imvanex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Imvanex : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (361.89 KB - PDF)

**First published:** 14/08/2014

**Last updated:** 16/06/2025

[View](/en/documents/procedural-steps-after/imvanex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Imvanex-H-C-002596-II-0108 : EPAR - Assessment report - Variation

Reference Number: EMA/484428/2024

English (EN) (1.04 MB - PDF)

**First published:** 16/10/2024

[View](/en/documents/variation-report/imvanex-h-c-002596-ii-0108-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Imvanex (II-108)

Adopted

Reference Number: EMA/418293/2024

English (EN) (129.53 KB - PDF)

**First published:** 19/09/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imvanex-ii-108_en.pdf)

Imvanex-H-C-PSUSA-00010119-202307 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/238395/2024

English (EN) (129.94 KB - PDF)

**First published:** 22/05/2024

[View](/en/documents/scientific-conclusion/imvanex-h-c-psusa-00010119-202307-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Imvanex-H-C-002596-II-0076 : EPAR - Assessment report - Variation

Reference Number: EMA/683534/2022

English (EN) (1.89 MB - PDF)

**First published:** 09/08/2022

[View](/en/documents/variation-report/imvanex-h-c-002596-ii-0076-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Imvanex (II-76)

Adopted

Reference Number: EMA/CHMP/642836/2022

English (EN) (107.72 KB - PDF)

**First published:** 22/07/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-imvanex-ii-76_en.pdf)

Imvanex-H-C-2596-PSUV-0007 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/521678/2014

English (EN) (101.49 KB - PDF)

**First published:** 27/08/2014

**Last updated:** 27/08/2014

[View](/en/documents/scientific-conclusion/imvanex-h-c-2596-psuv-0007-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Imvanex : EPAR - Public assessment report

Adopted

Reference Number: EMA/369203/2013

English (EN) (3.43 MB - PDF)

**First published:** 16/08/2013

**Last updated:** 16/08/2013

[View](/en/documents/assessment-report/imvanex-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Imvanex

Reference Number: EMA/CHMP/256704/2013

English (EN) (70.35 KB - PDF)

**First published:** 31/05/2013

**Last updated:** 31/05/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-imvanex_en.pdf)

#### News on Imvanex

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2024) 20/09/2024

[EMA recommends extending indication of mpox vaccine to adolescents](/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents) 19/09/2024

[EMA's Emergency Task Force advises on intradermal use of Imvanex / Jynneos against monkeypox](/en/news/emas-emergency-task-force-advises-intradermal-use-imvanex-jynneos-against-monkeypox) 19/08/2022

[EMA response to the monkeypox public health emergency](/en/news/ema-response-monkeypox-public-health-emergency) 27/07/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

[EMA recommends approval of Imvanex for the prevention of monkeypox disease](/en/news/ema-recommends-approval-imvanex-prevention-monkeypox-disease) 22/07/2022

[Monkeypox: EMA starts review for Imvanex](/en/news/monkeypox-ema-starts-review-imvanex) 28/06/2022

[European Medicines Agency recommends approval of 44 medicines for human use and six medicines for veterinary use in first half 2013](/en/news/european-medicines-agency-recommends-approval-44-medicines-human-use-six-medicines-veterinary-use-first-half-2013) 31/07/2013

#### More information on Imvanex

- [EMEA-001161-PIP02-11-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001161-pip02-11-m03)
- [Prospective Cohort Study and Emulated Target Trial to Estimate the Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in Germany (SEMVAc/TEMVAc) - post-authorisation study](https://catalogues.ema.europa.eu/study/50282)
- [Effectiveness and safety of MVA-BN vaccination against Mpox in at-risk individuals in the United States (USMVAc) (USMVAC study) - post-authorisation study](https://catalogues.ema.europa.eu/study/105127)

#### Topics

- [Mpox](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A67812)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 20/10/2025

## Share this page

[Back to top](#main-content)